Bausch Health: “We desired to buy more today, but we ran out of time. This thing is being placed on sale. There are shorts taking all of it the way in which down. It is sort of ridiculous. I desired to have the opportunity to purchase an enormous slug of it today, in order that’s how I feel for the [Charitable Trust].”
Accenture: “They crushed that stock. The business is unbelievable. They’d a terrific quarter. I’m saying to people [buy, buy, buy].”
Celularity: “That is one among the upper risk stocks on the market. The best way I’d have a look at it’s, be prepared to lose the whole lot but otherwise make quite a lot of money if it really works out.”
Manulife: “They tackle an excessive amount of risk, Manulife. I’m not there for the 5% [dividend yield]. I do not need it. An excessive amount of risk within the common stock.”
Marvell Technology: “It’s best to [keep buying more of it]. This company has two businesses: high-performance computing and 5G. We all know those are the 2 strongest areas. It has no PC business. It has no gaming. Marvell is a stock that we have been buying, buying, buying for the Charitable Trust, and I feel you must, too.”
Iron Mountain: “I like Iron Mountain. Good yield, very consistent business. [Buy, buy, buy].”
Disclosure: Cramer’s Charitable Trust owns shares of BHC and MRVL.
Join now for the CNBC Investing Club to follow Jim Cramer’s every move available in the market.
